Navigation Links
Ventas Names Chicago as Headquarters
Date:4/24/2008

borrowing; (h) the ability of the Company's operators and managers, as applicable, to deliver high quality services, to attract and retain qualified personnel and to attract residents and patients; (i) the results of litigation affecting the Company; (j) changes in general economic conditions and/or economic conditions in the markets in which the Company may, from time to time, compete; (k) the Company's ability to pay down, refinance, restructure and/or extend its indebtedness as it becomes due; (l) the movement of interest rates and the resulting impact on the value of and the accounting for the Company's interest rate swap agreement; (m) the Company's ability and willingness to maintain its qualification as a REIT due to economic, market, legal, tax or other considerations; (n) final determination of the Company's taxable net income for the year ended December 31, 2007 and for the year ending December 31, 2008; (o) the ability and willingness of the Company's tenants to renew their leases with the Company upon expiration of the leases and the Company's ability to relet its properties on the same or better terms in the event such leases expire and are not renewed by the existing tenants; (p) risks associated with the Company's seniors housing communities managed by Sunrise Senior Living, Inc. ("Sunrise"), including the timely delivery of accurate property-level financial results for the Company's properties; (q) factors causing volatility in the Company's revenues generated by its seniors housing communities managed by Sunrise, including without limitation national and regional economic conditions, costs of materials, energy, labor and services, employee benefit costs and professional and general liability claims; (r) the movement of U.S. and Canadian exchange rates; (s) year-over- year changes in the Consumer Price Index and the effect of those changes on the rent escalators, including the rent escalator for Master Lease 2 with Kindred, and the Company's earnings
'/>"/>
SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ventas Announces 2008 First Quarter Earnings Release Date and Conference Call
2. Ventas to Present at Credit Suisse 2008 Global Real Estate Conference
3. Ventas Announces Brush Departure
4. Ventas Appoints James D. Shelton and Robert D. Reed to Board
5. Ventas to Present at the Citi 2008 Global Property CEO Conference
6. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
7. Ventas Completes Previously Announced Sale of Common Stock
8. Ventas Enters Agreement to Sell Common Stock
9. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
10. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
11. Ventas Appoints Brush SVP - Senior Housing Development and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ersity College of Medicine research team led by Ya...of regulation in the cell division cycle, which co...cer begins. , Wang, an assistant professor of bi... the findings will lead to an improved ability to ...w drugs that kill cancer cells by inhibiting cell ...
(Date:11/21/2008)...l/ -- Heska Corporation,(Nasdaq: HSKA ) today a...f,Security Analysts, 12th Annual Biotech and Spec...77 Avenue of the Americas, 2nd Floor in New York, ...5 a.m. Eastern Time (7:35 a.m.,Mountain Time) and...eks,following the presentation through a link und...
(Date:11/21/2008)...antibiotic resistance from widespread use , ... with moderate to severe chronic obstructive pulmo...uency of exacerbations through a regular, low dose...The study, published in the first issue for Decemb...tical Care Medicine , found that twice-daily 250-m...
(Date:11/21/2008)...he University of Texas M. D. Anderson Cancer Cen... to eradicate breast cancer in Panama through the ...ch of the Americas today at an event with Laura Bu...n Fernandez de Torrijos, the First Lady of Panama....ve are the U.S. Department of State and Susan G. K...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3
...he treatment of many complex problems. According t...ue of Angiology if pine bark extract Pycnogenol? (...p of muscles. The reason and scientific basis beh...act improves blood flow to the muscles which speed...
...the MCD today said there was a rise in the breedin...s it launched //a special drive to check breeding ...uito breeding, responsible for the spread of the d...arious parts of the city especially in desert cool...
...ammatory drug Dicolofenec on the country's vulture...ed to withdraw licences for manufacturing it for v...director of the prominent NGO Bombay Natural Histo...sented a copy of Drug Controller General Ashwini K...
...posed to pesticides that is used for killing bugs ...son’s disease //. Parkinson's disease is a disorde... and so may affect movement, speech and posture. ...berta Frigerio and others studied 149 patients who...
Other Medicine News:Health News:A herbal delight for athletes in solving cramp and pain problems 2Health News:A herbal delight for athletes in solving cramp and pain problems 3
(Date:11/20/2008)...SE III TRIAL SHOW SIGNIFICANT, DECREASES IN P..., IN, FIBROMYALGIA PAT...ium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz Pharm...xt Brussels: UCB),announced today positive prelim...e III pivotal clinical trials of sodium oxybate (J...
(Date:11/20/2008)...Call/ -- Bionovo, Inc.,(Nasdaq: BNVI ) announce...1B,clinical trial of their lead drug candidate fo...he Society for Integrative Oncology,s Fifth Intern...any,s oral presentation was selected,as a top sco...he Best of the,SIO Session on November 20, 2008. ...
(Date:11/20/2008)...ta from a prospective,registry presented this wee...eatment with the Trellis(R) Peripheral Infusion Sy...) successfully breaks up the blood clot in most,p...ue, called isolated pharmacomechanical thrombolysi...an current catheter-directed thrombolysis,(CDT) t...
(Date:11/19/2008)...Science Corporation,researcher, Dan Tinker, prese...ual Conference in Washington, DC this week indicat...ers. The computerized brain plasticity-based,Bra...at target auditory and,language systems. The exe...ents in cognition by improving speed and accuracy ...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Using Early Stage Commercialization Activities to Build Long Term Success for the Bottom Line 8451 1Using Early Stage Commercialization Activities to Build Long Term Success for the Bottom Line 8451 2This Holiday Season Some Dream of a White Christmas The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 8449 1This Holiday Season Some Dream of a White Christmas The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 8449 2This Holiday Season Some Dream of a White Christmas The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 8449 3GeneGo Integrates With Cytoscape 2266 1GeneGo Integrates With Cytoscape 2266 2Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2264 1Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2264 2
...07 - Roche today announced,results of a small stud... treatment with Peg-Intron(R) (peginterferon alfa-... first 12 weeks, were,able to complete 12 weeks of... and ribavirin. Furthermore, 92 percent of,these p...rse of,treatment with PEGASYS. The data, which wer...
...rstCall/ -- Bristol-Myers,Squibb Company (NYSE: BM...ich showed that treatment with Baraclude (entecavi...adefovir at 48 weeks,-- a result that was also see...a from an open-label, randomized viral kinetics st...tigen (HBeAg),positive patients were presented at ...
Other Medicine Technology:Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 2Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 3Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 4Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 5Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 6Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
...um Eppendorf Style Low Binding, Graduated Pipet Ti...Pipettors.Reduces DNA and protein binding. Non-rea... completely by automation. RNAse & DNAse free. AVR...nd 10 racks/cs. AVR100 is the Cell Rack packaged 9...
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Like all Gilson disposable pipette tips, TowerPacks are available in a sterilized version. Each Sterilized TowerPack is individually wrapped in medical device-quality plastic to help protect tips fro
Medicine Products: